#1 Clinical Trials Search in Europe

Non-small cell lung cancer stage III – Trials in Disease

Go back

Clinical Trials for Non-small Cell Lung Cancer Stage III

Currently, 27 clinical trials are investigating new treatments for stage III non-small cell lung cancer across Europe. These trials examine various approaches including immunotherapy, targeted therapy, and combinations with chemotherapy and radiation, offering patients potential access to novel treatment strategies at different stages of their care journey.

Clinical trial locations

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

This trial is designed for patients who have previously participated in clinical studies involving durvalumab and are still benefiting from the treatment. To be eligible, patients must have received durvalumab in a previous study and be deemed suitable to continue by their doctor. They need to be able to receive a fixed dose of 1500 mg every four weeks.

Patients cannot join if they have other types of cancer not covered by the study, have not completed required previous treatments, have medical conditions interfering with study treatment, cannot follow study procedures or attend visits, are pregnant or breastfeeding, have severe allergies to the study medication, serious infections or illnesses, are currently participating in another clinical trial, or have a history of substance abuse or recent major surgery.

The study focuses on continuing treatment with durvalumab for patients who have completed a previous cancer study and are still experiencing benefits. This allows patients to maintain their positive response to treatment while researchers monitor safety and tolerability. Throughout the study, any serious side effects are tracked for up to 90 days after the last dose.

Durvalumab is an immunotherapy medication that helps the immune system fight cancer cells by blocking a protein that prevents immune system recognition of cancer cells. This allows the body’s natural defenses to better identify and destroy cancer cells.

Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance

This trial accepts patients who have locally advanced stage III non-small cell lung cancer that cannot be surgically removed and shows PD-L1 protein expression of 1% or higher. Eligible patients must have adequate bone marrow and organ function, weigh more than 30 kilograms, be 18 years or older, have good physical performance status, and be able to undergo combined chemotherapy, radiation therapy, and immunotherapy.

Patients are excluded if they have a history of small cell lung cancer, previous chest radiation, PD-L1 expression below 1%, metastatic disease, serious heart conditions, uncontrolled high blood pressure, active or untreated brain metastases, active autoimmune disease requiring treatment, current use of immune-suppressing medications, uncontrolled infections, recent participation in other clinical trials, pregnancy or breastfeeding, known allergies to study medications, inability to receive chemotherapy and radiation safely, inability to undergo FDG-PET scanning, or mental conditions affecting study compliance.

The trial evaluates whether using FDG-PET imaging to guide accelerated radiation treatment combined with chemotherapy and immunotherapy works as effectively as standard treatment. Patients receive radiation therapy together with platinum-based chemotherapy, followed by durvalumab immunotherapy treatment given through intravenous infusion for up to 12 months. Throughout the study, doctors monitor treatment response and side effects.

Durvalumab is an immunotherapy medication that helps the immune system fight cancer cells by blocking the PD-L1 protein, allowing immune cells to better recognize and attack tumors. Chemoradiotherapy combines chemotherapy drugs with radiation therapy to make cancer cells more sensitive to radiation treatment while using high-energy rays to destroy cancer cells.

Study of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer

To join this study, patients must be at least 18 years old, newly diagnosed with non-small cell lung cancer stages IIA to IIIA that can be surgically removed, and suitable for specific lung surgeries (lobectomy, sleeve resection, or bilobectomy). They need good overall health with WHO or ECOG performance status of 0 or 1, adequate organ and bone marrow function, life expectancy of at least 12 weeks, weight over 35 kg, and the ability to provide tumor samples for testing. Women who can have children must have a negative pregnancy test.

Patients cannot participate if they have other cancers besides stages II, III, or IIIA non-small cell lung cancer, are outside the specified age range, cannot safely undergo surgery, have serious health conditions interfering with the study, are pregnant or breastfeeding, have received certain recent treatments, or are unable to follow study procedures.

The trial examines IPH5201 and durvalumab as treatments given before and after surgery to determine effectiveness and safety in early-stage lung cancer patients. Treatment begins with neoadjuvant therapy using both medications through intravenous infusion to reduce tumor size. After surgery to remove the cancer, patients receive adjuvant treatment with continued durvalumab to eliminate remaining cancer cells and reduce recurrence risk. Regular follow-up appointments monitor recovery and check for any signs of cancer return.

IPH5201 is an investigational immunotherapy agent being studied for its potential to enhance the immune response against early-stage non-small cell lung cancer. Durvalumab is an approved monoclonal antibody and immune checkpoint inhibitor that blocks the PD-1 pathway, helping the immune system detect and fight cancer cells more effectively.

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Patients eligible for this study must have newly diagnosed resectable non-small cell lung cancer at stages IIA to IIIB, with adequate organ and pulmonary function, and a performance status of 0 or 1. They need to provide tumor samples for testing specific markers like PD-L1, EGFR, or ALK, and must not have received prior treatment for NSCLC.

Patients are excluded if they have other types of cancer, lung cancer not in early stages or not surgically removable, have received previous lung cancer treatments, have serious interfering health conditions, are pregnant or breastfeeding, or are unable to follow study procedures.

The trial evaluates the effectiveness and safety of multiple medications including volrustomig, carboplatin, falbikitug, paclitaxel, datopotamab deruxtecan, cisplatin, durvalumab, oleclumab, and monalizumab. These treatments are given through intravenous infusion both before surgery (neoadjuvant treatment) to shrink tumors and after surgery (adjuvant treatment) to eliminate remaining cancer cells. The study monitors how well tumors respond to treatment and tracks any side effects experienced by participants.

Durvalumab is an immunotherapy drug that blocks the PD-L1 protein, helping the immune system recognize and attack cancer cells more effectively. This medication is being evaluated as part of a combination therapy approach for treating resectable early-stage non-small cell lung cancer.

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

To be eligible, patients must provide written consent, have a mean resting corrected QT interval within specified limits, adequate bone marrow and organ function shown by blood tests, be over 18 years old, have confirmed stage III or IV NSCLC with documented KRAS G12C mutation, have received at least one previous treatment including a checkpoint inhibitor, have ECOG status 0-2, life expectancy of at least 12 weeks, at least one measurable tumor not previously treated with radiation, and if female with childbearing potential, use effective birth control and have negative pregnancy test. Male participants must agree to use barrier contraception.

Patients cannot participate if they do not have KRAS G12C-mutated non-small cell lung cancer, are not within the specified age range, or are considered part of a vulnerable population.

The trial tests sotorasib, taken as a film-coated tablet, to see how effective it is in reducing tumor size in patients with KRAS G12C-mutated non-small cell lung cancer. Patients receive sotorasib and are monitored over time to observe changes in tumor size and overall health. The study tracks how long patients can live without disease progression and how long they respond to treatment. Throughout the study, health assessments monitor safety and any side effects.

Sotorasib is a medication that works by targeting and inhibiting the KRAS G12C protein, which is involved in cancer cell growth and survival. By blocking this protein, sotorasib aims to slow down or stop cancer progression.

Study on Sotorasib for Patients with Unresectable Stage III Non-Small Cell Lung Cancer with KRAS Mutation

Eligible patients must be at least 18 years old, provide written informed consent, have a PD-L1 TPS of 1% or higher, lack EGFR mutations or ALK/ROS1/RET rearrangements, undergo baseline multidisciplinary assessment confirming suitability for curative-intent treatment, have pulmonary function tests done within 6 months of planned surgery, have at least one measurable lesion according to RECIST v1.1, have ECOG Performance Status of 0 or 1, be eligible for platinum doublet chemotherapy, and have adequate organ function shown by laboratory tests.

Patients are excluded if they have received prior lung cancer treatment, have serious heart problems or uncontrolled high blood pressure, have active infections, are pregnant or breastfeeding, have autoimmune diseases, have had organ transplants, have severe allergic reactions to similar drugs, or are currently in another clinical trial.

The study evaluates sotorasib for treating unresectable stage III NSCLC with KRAS p.G12C mutation. Patients receive treatment over time while being monitored for disease progression, overall survival, and safety. The trial aims to determine if sotorasib can extend the time patients live without cancer progression. Throughout the study, regular check-ups and tests monitor health and cancer progress, with baseline PET-CT scans required to confirm disease status.

Sotorasib is an oral medication specifically designed to target and inhibit the KRAS p.G12C protein, which drives cancer cell growth. By blocking this protein, the treatment aims to prevent cancer cells from proliferating.

Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

To join this study, patients must have histologically confirmed non-small cell lung cancer at stage IIB-IIIB, have a resectable and operable primary tumor as determined by a multidisciplinary team, be fit to receive platinum-based chemotherapy, have a known PD-L1 status without EGFR mutations or ALK translocations, have adequate blood/kidney/liver function, have ECOG performance status 0-1, be at least 18 years old, weigh more than 30 kilograms, and have a life expectancy of at least 12 weeks.

Patients cannot participate if they have other cancers not specified by the study, have not completed required previous treatments, have medical conditions interfering with study treatment, cannot follow study procedures or attend visits, are pregnant or breastfeeding, have severe allergies to study medication, serious infections or illnesses, are participating in another trial, have substance abuse history, or have had recent major surgery.

The trial examines whether adding durvalumab after initial chemotherapy and surgery improves outcomes for patients with resectable stage IIB-IIIB non-small cell lung cancer. Patients receive neoadjuvant treatment combining chemotherapy and durvalumab before surgery, followed by surgery to remove the tumor. After surgery, eligible patients continue with adjuvant durvalumab treatment to prevent cancer recurrence. Regular follow-up visits monitor health status, disease-free survival, overall survival, and any side effects.

Durvalumab is an immunotherapy drug administered as an intravenous infusion that blocks the PD-L1 protein, helping the immune system recognize and attack cancer cells more effectively after surgery and chemotherapy treatment.

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

To participate, patients must provide informed consent, be at least 18 years old, agree to use highly effective birth control (for those who can have children), be willing to attend scheduled visits and follow treatment plans, have confirmed stage IIIB/IIIC (unresectable or not suitable for radiotherapy) or stage IV NSCLC without EGFR or ALK mutations, have at least one measurable tumor, have ECOG performance status 0 or 1, have life expectancy over 3 months, have adequate organ function, and if female with childbearing potential, have negative pregnancy test at screening and before each dose.

Patients cannot participate if they have any other cancer besides NSCLC, received different cancer treatment within last 4 weeks, have severe heart problems or uncontrolled high blood pressure, have active infections, are pregnant or breastfeeding, have known allergies to study drugs, have history of severe allergic reactions, have significant liver or kidney disease, or participated in another trial within last 30 days.

The trial tests BNT327 in combination with chemotherapy to evaluate safety and effectiveness for treating non-small cell lung cancer. The study is divided into Phase II assessing safety and tolerability at different dose levels, and Phase III comparing effectiveness of BNT327 plus chemotherapy to pembrolizumab plus chemotherapy. Treatment is given through intravenous infusion with regular follow-up visits to monitor health and treatment effects over the study period.

BNT327 is an investigational immunotherapy drug administered intravenously that targets specific proteins on cancer cells to enhance the immune response. It is being studied in combination with standard chemotherapy for treating non-small cell lung cancer.

Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

Eligible patients must be at least 18 years old, agree to use effective birth control during treatment and for 6 months after last dose, provide written informed consent, have advanced stage 3 or 4 NSCLC that progressed or returned after previous treatment (stage 4 must have progressed after first treatment, stage 3 must have failed or be unable to receive local treatments), have had only one previous anti-PD-1/PD-L1 treatment with disease progression on or after that treatment, have at least one measurable cancer area, provide tumor tissue sample if available (with Medical Monitor approval if not), have ECOG performance status 0-1, have adequate organ function based on laboratory tests, and if female with childbearing potential, have negative pregnancy test before first dose.

Patients cannot participate if they have a different cancer type other than NSCLC, are not within the specified age range, cannot follow study procedures or take medication as required, have other serious interfering health conditions, are pregnant or breastfeeding, participated in another trial recently, have allergies to study medications, or cannot provide informed consent.

The study evaluates THIO and cemiplimab (LIBTAYO) for treating advanced NSCLC. THIO is given first, followed by cemiplimab, both administered through intravenous infusion. The trial monitors safety, effectiveness, and how the cancer responds to treatment over time. Researchers assess how long patients live without cancer progression, observe cancer response (including shrinkage or stabilization), track side effects and their severity, and evaluate overall survival.

THIO is an investigational anticancer agent being studied for safety and effectiveness when used in combination with cemiplimab. Cemiplimab (LIBTAYO) is an approved monoclonal antibody that blocks the PD-1 pathway, helping the immune system recognize and attack cancer cells more effectively.

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Eligible patients must have NSCLC diagnosis, ECOG performance status 0 or 1, confirmed stage IIB/IIIA/certain IIIB NSCLC, complete tumor resection, had mediastinal lymph node systematic sampling (dissection preferred), received 1-4 cycles of adjuvant platinum doublet chemotherapy (cisplatin or carboplatin with pemetrexed/gemcitabine/docetaxel/vinorelbine/etoposide/paclitaxel), recovered well from surgery and chemotherapy with no severe ongoing side effects, and not be from vulnerable populations.

Patients cannot participate if they have other cancers besides NSCLC, have not reached required age range, are part of vulnerable populations, or do not meet specific health conditions required.

The trial tests tiragolumab plus atezolizumab versus placebo plus atezolizumab to see if the combination can prevent cancer return after surgery and chemotherapy. Both medications are given through intravenous infusion. The study monitors safety, tolerability, and how long patients remain cancer-free. Participants receive treatment for up to 12 months with regular assessments tracking disease-free survival, overall survival, treatment response, and side effects.

Tiragolumab is an investigational immune checkpoint inhibitor administered intravenously that targets the TIGIT protein to enhance the immune system’s ability to fight cancer cells. Atezolizumab is an established immune checkpoint inhibitor that blocks the PD-L1 protein, helping the immune system recognize and attack cancer cells, already approved for treating PD-L1 positive NSCLC.

Study on Tislelizumab and Chemotherapy for Patients with Stage III PD-L1 Positive Non-Small Cell Lung Cancer

To participate, patients must provide written informed consent, have confirmed stage III disease, be at least 18 years old, have PD-L1 TPS of 1% or higher, lack EGFR mutations or ALK/ROS1/RET rearrangements, undergo baseline multidisciplinary assessment confirming suitability for curative-intent treatment, have pulmonary function tests within 6 months of planned surgery, have at least one measurable lesion per RECIST v1.1, have ECOG Performance Status 0 or 1, be eligible for platinum doublet chemotherapy, and have adequate organ function based on laboratory tests within 14 days before first dose.

Patients cannot join if they received any cancer treatment within last 4 weeks, have severe allergic reactions to study drugs, have active infections requiring treatment, have other serious medical conditions, are pregnant or breastfeeding, participated in another trial within last 4 weeks, have history of another cancer unless in remission for at least 5 years, have brain metastases unless treated and stable, have autoimmune diseases unless stable, or have history of drug or alcohol abuse within last 12 months.

The trial examines tislelizumab combined with platinum-based doublet chemotherapy for stage III PD-L1 positive NSCLC. Treatment begins with medications given through IV infusion to prepare patients for surgery by reducing tumor size. The goal is to achieve complete tumor resection with no visible cancer remaining after surgery. Throughout the trial, regular monitoring assesses treatment response, manages side effects, and includes physical exams, imaging tests, and laboratory tests. After completing treatment and surgery, regular follow-up ensures recovery and detects any cancer recurrence.

Tislelizumab is an immunotherapy drug administered as intravenous infusion that blocks the PD-1 protein on immune cells, helping the body’s immune system recognize and attack cancer cells more effectively when combined with standard chemotherapy.

The summaries above describe 10 major clinical trials currently recruiting or ongoing for stage III non-small cell lung cancer patients across Europe. The remaining 17 trials follow similar patterns, testing various combinations of immunotherapy drugs (such as durvalumab, atezolizumab, cemiplimab, and pembrolizumab), targeted therapies (like sotorasib and osimertinib), and chemotherapy approaches in different treatment settings.

Summary

The 27 clinical trials for stage III non-small cell lung cancer demonstrate significant geographic concentration in Western and Central Europe, with Germany, France, Spain, and Italy hosting the most trials. Several countries in Eastern Europe including Poland, Romania, Hungary, and Bulgaria also participate actively in these research programs.

Immunotherapy drugs feature prominently across trials, particularly durvalumab, which appears in multiple studies examining different treatment combinations and sequences. Other frequently studied immunotherapies include atezolizumab, cemiplimab, and pembrolizumab. Many trials test these medications in combination with platinum-based chemotherapy and radiation therapy.

The trials encompass different treatment approaches including neoadjuvant therapy (before surgery), adjuvant therapy (after surgery), and treatments for unresectable tumors. Several studies specifically target patients with particular genetic mutations such as EGFR, ALK, or KRAS G12C, reflecting the growing importance of personalized medicine in lung cancer treatment.

Notable trends include increasing focus on combination therapies, extended follow-up periods to assess long-term outcomes, and attention to quality of life measures alongside traditional survival endpoints. Some trials specifically address elderly or frail patients who cannot tolerate standard chemotherapy, representing an important underserved population.

Ongoing Clinical Trials on Non-small cell lung cancer stage III

  • Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Estonia France Germany Ireland Italy +1

  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary Poland Portugal Romania

  • Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Hungary Italy +3

  • Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Durvalumab with chemotherapy (paclitaxel, cisplatin, carboplatin, vinorelbine) in patients with stage IIIA/B non-small cell lung cancer that can be removed by surgery

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Hungary Poland

  • Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Estonia France Ireland Italy +1

  • Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Hungary Ireland Italy Portugal +1

  • Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Greece +5

More information about
Non-small cell lung cancer stage III:

Connected medications: